There are no Focus articles on GWPRF.
There are no News articles on GWPRF.
We currently have no Breaking News on this stock.
GWPRF vs. ETF Alternatives
GW is a pharmaceutical group developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic conditions. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is... More